Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 1
2000 1
2003 2
2004 2
2005 2
2006 2
2008 1
2013 2
2014 1
2017 1
2018 1
2019 3
2020 1
2021 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kvam e[au] (82 results)?
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: kvas e. J Neurol. 2023 Jun;270(6):3103-3111. doi: 10.1007/s00415-023-11644-y. Epub 2023 Mar 2. J Neurol. 2023. PMID: 36862148 Free PMC article.
Real-life use of oral disease-modifying treatments in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: kvas e. Acta Neurol Scand. 2019 Jul;140(1):32-39. doi: 10.1111/ane.13097. Epub 2019 Apr 22. Acta Neurol Scand. 2019. PMID: 30958901 Free PMC article.
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser T, Seiberl M, Feige J, Bieler L, Radlberger RF, O'Sullivan C, Pilz G, Harrer A, Schwenker K, Haschke-Becher E, Machegger L, Grimm J, Redlberger-Fritz M, Buchmann A, Khalil M, Kvas E, Trinka E, Wipfler P. Moser T, et al. Among authors: kvas e. Front Immunol. 2021 Aug 26;12:718895. doi: 10.3389/fimmu.2021.718895. eCollection 2021. Front Immunol. 2021. PMID: 34512642 Free PMC article. Clinical Trial.
Real-life clinical use of natalizumab and fingolimod in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T. Guger M, et al. Among authors: kvas e. Acta Neurol Scand. 2018 Feb;137(2):181-187. doi: 10.1111/ane.12864. Epub 2017 Nov 20. Acta Neurol Scand. 2018. PMID: 29159801
D-dimer in acute aortic dissection.
Weber T, Högler S, Auer J, Berent R, Lassnig E, Kvas E, Eber B. Weber T, et al. Among authors: kvas e. Chest. 2003 May;123(5):1375-8. doi: 10.1378/chest.123.5.1375. Chest. 2003. PMID: 12740250
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: kvas e. J Neurol. 2021 Nov;268(11):4303-4310. doi: 10.1007/s00415-021-10559-w. Epub 2021 Apr 22. J Neurol. 2021. PMID: 33890167 Free PMC article.
23 results